



Patients name _____

Address _____

Phone no. _____

E-mail _____

DOB _____ NHI _____ ACC _____

Insurance Yes No Provider _____

Referring Practitioner

Name _____ NZNM provider # _____

Phone no. _____ Date _____

Please send all therapy related correspondence to _____

Signature _____

Diagnosis

Reason for referral _____

Prostate Cancer related history and previous treatment _____

Other Medical History _____

Current Medication and Doses _____

Allergies _____

ECOG _____

Current Symptoms _____

Most recent PSMA PET-CT Imaging: _____ Date _____ Site _____

Most recent FDG PET-CT Imaging: _____ Date _____ Site _____

Kindly attach most recent blood results:
 2 latest consecutive PSA Levels FBC U&E LFT



Eligibility criteria for PSMA Therapy

¹⁷⁷Lu-PSMA will be administered following assessment of suitability by a Nuclear Medicine Specialist and managed in close collaboration with the patient's medical oncologist. The following criteria should be met in order to be suitable for ¹⁷⁷Lu-PSMA.

Inclusion criteria

1. Diagnosis of mCRPC
2. Progression or intolerance on a novel anti-androgen therapy
3. Prior therapy with at least one taxane cytotoxic (these agents may have been received upfront for metastatic hormone-sensitive prostate cancer) or the patient is symptomatic* and assessed as unfit for chemotherapy
4. Evidence of disease progression defined by one of:
 - a. Rising PSA (at least 2 consecutive rises greater than 1 week apart) (PCWG3 criteria)
 - b. Radiographic progression on CT scan, bone scan or PSMA PET/CT
 - c. Clinical progression defined by cancer-related pain requiring regular analgesia and/or radiotherapy for site of cancer-related pain within the previous 12 weeks
5. Ongoing treatment with androgen deprivation therapy (ADT) unless history of bilateral orchidectomy
6. Adequate haematological, renal and hepatic functions as defined by
 - a. Absolute neutrophil count $>1.5 \times 10^9 /L$
 - b. Platelet count $>100 \times 10^9 /L$
 - c. Haemoglobin ≥ 90 g/L (transfusion permissible)
 - d. Albumin ≥ 25 g/L (unless long-standing owing to chronic condition)
 - e. eGFR ≥ 30 ml/min
- 7 Performance status of 0-3 on the ECOG Performance Scale
8. Life expectancy greater than 6 months
9. PSMA and FDG PET/CT within 2 months of commencing treatment

Exclusion criteria for PSMA Therapy

1. Symptomatic cord compression, or clinical, or imaging findings concerning for impending cord compression